Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMitCEBO Plus G-CSF in Good-Prognosis HIV-Related Lymphoma
NCT00032149Phase 2Unknown
- Sponsor
- Lymphoma Trials Office
- Start
- Oct 2001
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone, cyclophosphamide, etoposide, vincristine, bleomycin and 2 more in non-Hodgkin lymphoma (NHL), sponsored by Lymphoma Trials Office. Primary endpoints: Toxicity, Response Rate and 2 more. Status: unknown.
02
Drugs
mitoxantronecyclophosphamideetoposidevincristinebleomycin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00032149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032149.